Bli medlem
Bli medlem

Du är här


Active Biotech: Active Biotech and Ipsen announce their decision to discontinue the development of tasquinimod in prostate cancer

Lund (Sweden) and Paris (France), 16 April 2015
- Active Biotech (NASDAQ STOCKHOLM: ACTI) and Ipsen (Euronext: IPN; ADR:
IPSEY) today announced top line results of the 10TASQ10 study. While the
study showed that tasquinimod reduced the risk of radiographic cancer
progression or death compared to placebo (rPFS, HR=0.69, CI 95%: 0.60 - 0.80)
in patients with metastatic castration resistant prostate cancer (mCRPC) who
have not received chemotherapy, tasquinimod did not extend overall survival
(OS, HR=1.09, CI 95%: 0.94 - 1.28).

Efficacy results together with preliminary safety data do not support positive
benefit risk balance in this population. Therefore the companies have decided
to discontinue all studies in prostate cancer. Full results will be presented
at an upcoming scientific conference.

Marc de Garidel, Chairman and Chief Executive Officer of Ipsen
stated: "We are disappointed for prostate cancer patients. Ipsen remains
committed to oncology.
Weare grateful to the clinicians, caregivers, patients and their families who
were involved in this study."

Professor Tomas Leanderson, President
and Chief Executive Officer
of Active Biotech
"The outcome of the 10TASQ10 study is a major disappointment based on the
promising phase II results. However, the data at hand is unambiguous and
cannot motivate further development of tasquinimod in this patient
population. I want to thank the clinicians, caregivers, patients and their
families who were involved in this study."

Ipsen and Active Biotech are in communication with trial investigators, ethics
committees and the relevant regulatory authorities, to provide them with
updated and current information in compliance with local regulations. The
companies are working with trial investigators and local regulatory
authorities to ensure that patients who participated in the tasquinimod
trials are transitioned to appropriate therapies so that trial participants
receive appropriate care.

About tasquinimod

Tasquinimod is a novel oral immunotherapy that targets the tumor
microenvironment by binding to S100A9 and modulating regulatory myeloid cell
functions, exerting immunomodulatory, anti-angiogenic and anti-metastatic
properties. Today the development of tasquinimod principally has been focused
on the treatment of prostate cancer, but early clinical studies in other
cancer indications are performed.

About the 10TASQ10 trial

The 10TASQ10 trial is a randomized, double-blind, placebo-controlled, global
Phase III clinical trial evaluating tasquinimod in patients with metastatic
castration resistant prostate cancer (mCRPC) who have not yet received
chemotherapy. The aim of the 10TASQ10 study is to confirm tasquinimod's
efficacy, with radiological Progression Free Survival (rPFS) as primary
endpoint and overall survival (OS) as key secondary endpoint. The Phase III
10TASQ10 trial met its enrollment target in December 2012 with more than
1,200 randomized patients as planned in the clinical protocol.

About Active Biotech

Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company
with focus on neurodegenerative diseases and cancer. Projects in pivotal
phase are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, and
tasquinimod, an oral immunomodulatory, anti-metastatic substance for the
treatment of prostate cancer. The objective of the preclinical ISI project is
to produce new, patentable chemical compounds for treatment of diseases in
the company's focus areas. Please visitwww.activebiotech.comfor more

About Ipsen

Ipsen is a global specialty-driven biotechnological group with total sales
exceeding €1.2 billion in 2014. Ipsen sells more than 20 drugs in more than
115 countries, with a direct commercial presence in 30 countries. Ipsen's
ambition is to become a leader in specialty healthcare solutions for targeted
debilitating diseases. Its development strategy is supported by 3 franchises:
neurology, endocrinology and urology-oncology. Ipsen's commitment to oncology
is exemplified through its growing portfolio of key therapies improving the
care of patients suffering from prostate cancer, bladder cancer or
neuro-endocrine tumors. Ipsen also has a significant presence in primary
care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D
is focused on its innovative and differentiated technological platforms,
peptides and toxins, located in the heart of the leading biotechnological and
life sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge, US). In
2014, R&D expenditure totaled close to €187 million, representing about 15%
of Group sales. The Group has more than 4,500 employees worldwide. Ipsen's
shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code:
FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The
Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I
American Depositary Receipt (ADR) program, which trade on the
over-the-counter market in the United States under the symbol IPSEY. For more
information on Ipsen,

Ipsen Forward Looking Statements

The forward-looking statements, objectives and targets contained herein are
based on the Group's management strategy, current views and assumptions. Such
statements involve known and unknown risks and uncertainties that may cause
actual results, performance or events to differ materially from those
anticipated herein. All of the above risks could affect the Group's future
ability to achieve its financial targets, which were set assuming reasonable
macroeconomic conditions based on the information available today. Use of the
words "believes," "anticipates" and "expects" and similar expressions are
intended to identify forward-looking statements, including the Group's
expectations regarding future events, including regulatory filings and
determinations. Moreover, the targets described in this document were
prepared without taking into account external growth assumptions and
potential future acquisitions, which may alter these parameters. These
objectives are based on data and assumptions regarded as reasonable by the
Group. These targets depend on conditions or facts likely to happen in the
future, and not exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain risks and
uncertainties, notably the fact that a promising product in early development
phase or clinical trial may end up never being launched on the market or
reaching its commercial targets, notably for regulatory or competition
reasons. The Group must face or might face competition from generic products
that might translate into a loss of market share. Furthermore, the Research
and Development process involves several stages each of which involves the
substantial risk that the Group may fail to achieve its objectives and be
forced to abandon its efforts with regards to a product in which it has
invested significant sums. Therefore, the Group cannot be certain that
favourable results obtained during pre-clinical trials will be confirmed
subsequently during clinical trials, or that the results of clinical trials
will be sufficient to demonstrate the safe and effective nature of the
product concerned. There can be no guarantees a product will receive the
necessary regulatory approvals or that the product will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks
or uncertainties materialize, actual results may differ materially from those
set forth in the forward-looking statements. Other risks and uncertainties
include but are not limited to, general industry conditions and competition;
general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of pharmaceutical industry regulation and health
care legislation; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining
regulatory approval; the Group's ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the effectiveness
of the Group's patents and other protections for innovative products; and the
exposure to litigation, including patent litigation, and/or regulatory
actions. The Group also depends on third parties to develop and market some
of its products which could potentially generate substantial royalties; these
partners could behave in such ways which could cause damage to the Group's
activities and financial results. The Group cannot be certain that its
partners will fulfil their obligations. It might be unable to obtain any
benefit from those agreements. A default by any of the Group's partners could
generate lower revenues than expected. Such situations could have a negative
impact on the Group's business, financial position or performance. The Group
expressly disclaims any obligation or undertaking to update or revise any
forward looking statements, targets or estimates contained in this press
release to reflect any change in events, conditions, assumptions or
circumstances on which any such statements are based, unless so required by
applicable law. The Group's business is subject to the risk factors outlined
in its registration documents filed with the French Autorité des Marchés

Active Biotech's Safe Harbor Statement in Accordance with the Swedish
Securities Market Act:

This press release contains certain forward-looking statements. Such
forward-looking statements involve known and unknown risks, uncertainties and
other important factors that could cause the actual results, performance or
achievements of the company, or industry results, to differ materially from
any future results, performance or achievement implied by the forward-looking
statements. The company does not undertake any obligation to update or
publicly release any revisions to forward-looking statements to reflect
events, circumstances or changes in expectations after the date of this press

For further information:

Active Biotech

| Tomas Leanderson, President&CEO Hans Kolam, CFO |
|Tel: +46 46 19 20 95 |
| Tel: +46 46 19 20 44 |
| |
| Ipsen Brigitte Le Guennec |
| ...

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.